Klinik Landstrabe — Clinical Trial Site

20 Registered trials

3 Currently recruiting

Organisation

Klinik Landstrabe

Location

Vienna, Austria

Identifier

ORG-100029026

Address

Juchgasse 25, Landstraße, 1030, Austria

Departments

1. Medical Department
1. Medizinische Abteilung
1.Med. Abteilung
1st Medical Department
1st Medical Department of Diabetology, Endocrinology and Oncology
1st Medical Department with Diabetology, Endocrinology and Nephrology
1st Medical Department with Diabetology, Endocrinology and Oncology
2nd Medical Department with cardiology and internal intensive care medicine
Department of Internal Medicine I with Diabetology, Endocrinology and Nephrology
dermatology
Medical Department of Diabetology, Endocrinology and Nephrology
N/A

Clinical trials at this site (20)

Search interface

SGLT2 lnhibition in Hemodialysis (DAPA-HD) Pending

2024-518591-31-00 Chronic Kidney Disease 4
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TR… Ended

2023-506082-60-00 Chronic Kidney Disease 4 2023-02-28
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended

2023-509709-63-00 Chronic Kidney Disease and Albuminuria 4 2024-07-30
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended

2022-502647-35-00 Non-alcoholic steatohepatitis 4 2023-09-01
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24